Pfizer (PFE) Asset Writedowns and Impairment (2009 - 2026)

Pfizer (PFE) has 18 years of Asset Writedowns and Impairment data on file, last reported at $32.0 million in Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $32.0 million, down 85.71% year-over-year; the trailing twelve-month figure through Mar 2026 was -$192.0 million (down 132.0% YoY), and the FY2023 annual result was $3.0 billion, up 445.45% from the prior year.
• Asset Writedowns and Impairment climbed to $32.0 million in Q1 2026 per PFE's latest filing, from -$577.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $2.5 billion in Q4 2023 and troughed at -$577.0 million in Q4 2025.
• A 5-year average of $310.0 million and a median of $200.0 million in 2022 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2023 and 2026: Asset Writedowns and Impairment jumped 770.97% in 2023, then plunged 85.71% in 2026.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $200.0 million in 2022, then jumped by 1150.5% to $2.5 billion in 2023, then sank by 90.4% to $240.0 million in 2024, then plunged by 340.42% to -$577.0 million in 2025, then surged by 105.55% to $32.0 million in 2026.
• Business Quant data shows PFE's Asset Writedowns and Impairment at $32.0 million in Q1 2026, -$577.0 million in Q4 2025, and $260.0 million in Q3 2025.